Infliximab Should Be Restarted Approximately 2 Weeks After Surgery
For patients on infliximab undergoing elective surgery, restart the medication once the wound shows evidence of healing, sutures/staples are removed, there is no significant swelling, erythema, or drainage, and no ongoing infection—typically around 14 days postoperatively 1.
Timing of Resumption
The 2022 ACR/AAHKS guideline provides clear direction on when to restart infliximab after surgery 1:
- Wait for clinical wound healing markers: The wound must demonstrate adequate healing with sutures/staples removed, absence of significant swelling, erythema, or drainage
- Rule out infection: Ensure there is no surgical site infection or any other active infection
- Typical timeframe: This usually occurs around 14 days (2 weeks) after surgery
Evidence Supporting Early Restart
The guideline notes that delaying infliximab restart beyond 4 weeks after surgery may actually worsen outcomes 1. A Medicare database study found better outcomes in patients who restarted infliximab within 4 weeks compared to those who delayed longer—though the authors noted that postoperative complications themselves often caused the delays, not the other way around.
Research specifically in Crohn's disease patients supports the safety of early infliximab administration, with one study showing no increase in postoperative complications when infliximab was started as early as 14-25 days (mean 20 days) after intestinal resection 2. There were no serious adverse events, wound healing complications, or infections in the infliximab group.
Critical Considerations
When to Delay Restart Beyond 2 Weeks:
- History of prior severe infections
- History of prior prosthetic joint infection
- Evidence of delayed wound healing
- Any signs of surgical site infection
- Presence of non-surgical site infection
Pharmacokinetic Context:
Infliximab has a terminal half-life of 7.7 to 9.5 days 3, meaning drug levels are essentially cleared by 2-3 weeks post-last dose. This supports the 2-week restart window as a reasonable balance between maintaining disease control and allowing initial wound healing.
Disease-Specific Nuances
For inflammatory bowel disease patients, the evidence suggests even earlier restart may be safe. Studies show infliximab given 2-4 weeks postoperatively for Crohn's disease prevention was not associated with increased complications 2, 4.
For rheumatoid arthritis and other rheumatic diseases, the guideline applies the same 14-day restart principle across all biologic DMARDs, including infliximab 1.
Common Pitfall to Avoid
Do not wait unnecessarily long to restart infliximab. The guideline emphasizes that outcomes may be worse when restart is delayed beyond 4 weeks, likely due to disease flares that can complicate recovery 1. The goal is to restart as soon as it is safe to do so—around 2 weeks—rather than adopting an overly conservative approach that risks disease activity.